The 2022 CMHC Spring recorded sessions highlight the latest updates in CKD, heart failure, hypertension, type 2 diabetes, dyslipidemia, lifestyle management, obesity, and cardiovascular health, as well as translate cutting-edge medical research into practical, clinical strategies for preventing, delaying, and managing cardio-renal-metabolic disorders.

On Demand Registration

All live meeting attendees receive complimentary access. If you haven’t received an email with instructions to access yet to please email [email protected]

2022 Spring On Demand Accreditation Information

Agenda

OPENING REMARKS & SESSION I: CARDIO-RENAL

Chair Introduction
George L. Bakris, MD

Outcomes Trials in Chronic Kidney Disease
Rajiv Agarwal, MD; Katherine R. Tuttle, MD
I. Improving Renal Outcomes with SGLT-2 Inhibitors and GLP-1 RAs: Data, Interpretations, and Future Outlook
II. CKD Challenging Case & Expert Panel Discussion

Mini Break

Outcomes Trials in Heart Failure
I. SGLT-2is and ARNI Across the HF Spectrum – Alanna A. Morris MD
II. New and Emerging Treatment Targets in Heart Failure – Ileana L Piña, MD
III. ATTR-CM in African Americans: Advances in Diagnosis and Treatment to Help Reduce Disparities and Improve Outcomes This session is supported in part by an educational grant from Alnylam Pharmaceuticals, Inc.
Keith C. Ferdinand, MD
IV. HF Challenging Cases & Expert Panel Discussion

Emerging Developments in Hypertension
I. Emerging Treatments for Hypertension – Keith C. Ferdinand, MD
II. Resistant Hypertension: Old and New – Debbie Cohen, MD
III. Expert Panel Discussion & Audience Q & A

KEYNOTE ADDRESS

Cardiometabolic Centers of Excellence – a novel care delivery model to improve quality and outcomes in cardiometabolic disease
Mikhail N. Kosiborod, MD

Agenda

SESSION II: DIABETES MANAGEMENT

Chair Introduction
Anne L. Peters, MD

Prediabetes: Screening, Diagnosis, and Management
Leigh Perreault, MD

Continuous Glucose Monitoring: Going Beyond HbA1c to Optimize and Individualize the Management of Type 2 Diabetes
This session is supported by Abbott Diabetes.
Viral Shah, MD

Dual GLP-1/GIP Agonists: Are They the Next Big Thing in Diabetes Treatment?
Athena Philis-Tsimikas, MD

How Can We Converge the Glucocentric and Cardio-Renal Risk Management in Diabetes Patients?
Lawrence A. Leiter MD

The Evolution of Insulin: A 2022 Update
Grazia Aleppo, MD, FACE, FACP

How Can We Converge the Glucocentric and Cardio-Renal Risk Management in Diabetes Patients?
Lawrence A. Leiter MD

Expert Panel Discussion & Audience Q & A
Moderator: Anne L. Peters, MD
Panelists: Viral Shah, MD ; Athena Philis-Tsimikas, MD; Lawrence A. Leiter MD; Grazia Aleppo, MD, FACE, FACP; Steven J. Russell MD, PhD

Closing Remarks
Anne L. Peters, MD

Agenda

SESSION III: OBESITY AND LIFESTYLE MEDICINE

Chair Introduction and Opening Remarks
Robert H. Eckel, MD

Lifestyle Approaches to Target Obesity & Cardiometabolic Risk
I. Physical Activity – John Jakicic, PhD
II. Nutrition and Cardiometabolic Risk – Maya Vadiveloo, PhD, RD
III. Motivational Interviewing and Behavioral Strategies to Address Weight Management – Holly R. Wyatt, MD

The Evolving Landscape of NAFLD and NASH
Kenneth Cusi, MD

To Be Resolved: Which Approach is Better for Weight Loss?
I. Medical Management – Holly R. Wyatt, MD
II. Metabolic Surgery – Donna H. Ryan, MD
III. Clinical Implications: Expert Discussions & Audience Q/A

Morning Break & Exhibits

Addressing Bias, Stigma & Racial Disparities in Obesity Care
Fatima C. Stanford, MD

Challenging Cases & Expert Panel Discussion
Moderator: Robert H. Eckel, MD
Panelists: John Jakicic, PhD; Maya Vadiveloo, PhD, RD; Holly R. Wyatt, MD; Fatima C. Stanford, MD; Donna H. Ryan, MD

Closing Remarks
Robert H. Eckel, MD

Agenda

SESSION IV: DYSLIPIDEMIA/ATHEROSCLEROSIS/THROMBOSIS

Chair Introduction
Christie M. Ballantyne, MD

ASCVD Risk Assessment and Prevention: Where Do We Stand Now?
Salim S. Virani, MD

LDL-C-Lowering Therapies: New Approaches to Address Old Challenges
Pam R. Taub, MD

Lp(a) and Cardiovascular Risk
Michael Wilkinson, MD

What’s the Scoop with Triglycerides and ASCVD Risk?
Karol E. Watson, MD

The Spectrum of Familial Hypercholesterolemia
Robert S. Rosenson, MD

Updates in Antithrombotic Therapy for the Cardiometabolic Patient
Roxana Mehran, MD

Challenging Cases & Expert Panel Discussion and Q&A
Moderator: Christie M. Ballantyne, MD
Panelists: Robert H. Eckel, MD; Salim S. Virani, MD; Pam R. Taub, MD; Michael Wilkinson, MD; Karol E. Watson, MD; Robert S. Rosenson, MD; Roxana Mehran, MD

Closing Remarks
Christie M. Ballantyne, MD

Agenda

GREAT DEBATES IN CARDIOMETABOLIC MEDICINE

Introduction and Opening Remarks
Christie M. Ballantyne, MD

Do patients benefit from Omega-3 Fatty Acids for CVD Prevention?
Christie M. Ballantyne, MD; Michael Miller, MD; Karol E. Watson, MD
I. Yes
II. No
III. Expert Discussions & Audience Q/A

What is the Standard of Care for Heart Failure with Preserved Ejection Fraction (HFpEF)?
Ileana L Piña, MD; Mikhail N. Kosiborod, MD; Alanna A. Morris, MD
I. SGLT-2 Inhibitors
II. ARNI and Others
III. Expert Discussions & Audience Q/A

The Plate Debate: Which Approach is Better for the Management of Obesity and Cardiometabolic Risk?
Robert H. Eckel, MD; Monica Aggarwal, MD; David Ludwig, MD; Holly R. Wyatt, MD
I. Plant-based diets
II. Low-carb diets
III. It’s more complex than that
IV. Expert Discussions & Audience Q/A

Closing Remarks
Christie M. Ballantyne, MD

Additional  Information

Click below to download the Live Meeting Conference Guide
or visit the PME Library to view non-CME activities from the meeting